Tetraphase Pharmaceuticals (TTPH) Releases Earnings Results
Tetraphase Pharmaceuticals (NASDAQ:TTPH) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. The business had revenue of $1.15 million during the quarter, compared to the consensus estimate of $2.09 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.
NASDAQ:TTPH traded down $0.08 during mid-day trading on Friday, hitting $2.17. 808,354 shares of the company traded hands, compared to its average volume of 678,728. Tetraphase Pharmaceuticals has a one year low of $2.01 and a one year high of $6.97. The firm has a market capitalization of $118.93 million, a PE ratio of -0.83 and a beta of 2.67.
A number of research firms have commented on TTPH. HC Wainwright reissued a “buy” rating on shares of Tetraphase Pharmaceuticals in a report on Monday, July 16th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Friday, August 3rd. ValuEngine lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 30th. Finally, Piper Jaffray Companies cut their price target on Tetraphase Pharmaceuticals to $6.00 and set an “overweight” rating for the company in a report on Thursday, October 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $6.16.
COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals (TTPH) Releases Earnings Results” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2018/11/10/tetraphase-pharmaceuticals-ttph-releases-earnings-results.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.